Myeloproliferative Neoplasms (MPN)

December 10th 2024

Two posters presented at the 2024 American Society of Hematology meeting bolster evidence supporting the long-term clinical benefits of ruxolitinib for polycythemia vera and chronic graft-vs-host disease.

December 10th 2024

Research presented at the 66th American Society of Hematology Annual Meeting revealed that a genetic variant enriched in Andean populations, associated with reduced inflammation and improved response to ropeginterferon-α, could guide more precise treatments for polycythemia vera (PV) and essential thrombocythemia.

November 29th 2024

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the clinic.

November 14th 2024

The key driver in both sets of findings is the relationship between neutrophils and inflammation.